Local mitochondrial-endolysosomal microfusion cleaves voltage- dependent anion channel 1 to promote survival in hypoxia by Brahimi-Horn, M. Christiane et al.
RESEARCH OUTPUTS / RÉSULTATS DE RECHERCHE
Author(s) - Auteur(s) :
Publication date - Date de publication :
Permanent link - Permalien :
Rights / License - Licence de droit d’auteur :
Bibliothèque Universitaire Moretus Plantin
Institutional Repository - Research Portal
Dépôt Institutionnel - Portail de la Recherche
researchportal.unamur.be
Local mitochondrial-endolysosomal microfusion cleaves voltage- dependent anion
channel 1 to promote survival in hypoxia
Brahimi-Horn, M. Christiane; Lacas-Gervais, Sandra; Adaixo, Ricardo; Ilc, Karine; Rouleau,
Matthieu; Notte, Annick; Dieu, Marc; Michiels, Carine; Voeltzel, Thibault; Maguer-Satta,
Véronique; Pelletier, Joffrey; Ilie, Marius; Hofman, Paul; Manoury, Bénédicte; Schmidt,








Early version, also known as pre-print
Link to publication
Citation for pulished version (HARVARD):
Brahimi-Horn, MC, Lacas-Gervais, S, Adaixo, R, Ilc, K, Rouleau, M, Notte, A, Dieu, M, Michiels, C, Voeltzel, T,
Maguer-Satta, V, Pelletier, J, Ilie, M, Hofman, P, Manoury, B, Schmidt, A, Hiller, S, Pouysségur, J & Mazure, NM
2015, 'Local mitochondrial-endolysosomal microfusion cleaves voltage- dependent anion channel 1 to promote
survival in hypoxia' Molecular Cell Biology, vol. 35, no. 9, pp. 1491-1505. https://doi.org/10.1128/MCB.01402-14
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 21. May. 2019
Local Mitochondrial-Endolysosomal Microfusion Cleaves Voltage-
Dependent Anion Channel 1 To Promote Survival in Hypoxia
M. Christiane Brahimi-Horn,a Sandra Lacas-Gervais,b Ricardo Adaixo,c Karine Ilc,a Matthieu Rouleau,d Annick Notte,e Marc Dieu,e
Carine Michiels,e Thibault Voeltzel,f Véronique Maguer-Satta,f Joffrey Pelletier,a Marius Ilie,a,g Paul Hofman,a,g Bénédicte Manoury,h
Alexander Schmidt,c Sebastian Hiller,c Jacques Pouysségur,a,i Nathalie M. Mazurea
Institute for Research on Cancer and Aging of Nice, CNRS-UMR 7284-INSERM U1081, University of Nice Sophia-Antipolis, Centre Antoine Lacassagne, Nice, Francea; Centre
Commun de Microscopie Appliquée, University of Nice Sophia-Antipolis, Nice, Franceb; Biozentrum, University of Basel, Basel, Switzerlandc; Laboratoire de
PhysioMédecine Moléculaire, UMR 7370 CNRS, University of Nice Sophia-Antipolis, Faculty of Medicine, Nice, Franced; URBC-NARILIS, University of Namur, Namur,
Belgiume; Centre de Recherche en Cancérologie de Lyon, INSERM U1052, CNRS U5286, Centre Léon Bérard, Lyon, Francef; Human Tissue Biobank Unit/CRB and
Laboratory of Clinical and Experimental Pathology, Louis Pasteur Hospital, Nice, Franceg; INSERM U1013, Hôpital Necker, Paris, Franceh; Centre Scientifique de Monaco
(CSM), Monacoi
The oxygen-limiting (hypoxic) microenvironment of tumors induces metabolic reprogramming and cell survival, but the under-
lying mechanisms involving mitochondria remain poorly understood. We previously demonstrated that hypoxia-inducible fac-
tor 1 mediates the hyperfusion of mitochondria by inducing Bcl-2/adenovirus E1B 19-kDa interacting protein 3 and posttransla-
tional truncation of the mitochondrial ATP transporter outer membrane voltage-dependent anion channel 1 in hypoxic cells. In
addition, we showed that truncation is associated with increased resistance to drug-induced apoptosis and is indicative of in-
creased patient chemoresistance. We now show that silencing of the tumor suppressor TP53 decreases truncation and increases
drug-induced apoptosis. We also show that TP53 regulates truncation through induction of the mitochondrial protein Mieap.
While we found that truncation was independent of mitophagy, we observed local microfusion between mitochondria and en-
dolysosomes in hypoxic cells in culture and in patients’ tumor tissues. Since we found that the endolysosomal asparagine endo-
peptidase was responsible for truncation, we propose that it is a readout of mitochondrial-endolysosomal microfusion in hyp-
oxia. These novel findings provide the framework for a better understanding of hypoxic cell metabolism and cell survival
through mitochondrial-endolysosomal microfusion regulated by hypoxia-inducible factor 1 and TP53.
Hypoxia is a natural occurring stress that results in compensa-tory changes in metabolism and cell survival during embry-
onic development and tumor growth. Hypoxia stabilizes and ac-
tivates the transcription factor hypoxia-inducible factor (HIF)
through inhibition of oxygen-dependent hydroxylases that ear-
mark the alpha subunit of HIF for proteasomal degradation (1).
HIF induces or represses the expression of genes implicated in a
myriad of functions, including those regulating metabolism and
resistance to drug-induced cell death. Genes coding for the en-
zymes of the glycolytic pathway, including hexokinase, are highly
induced by HIF-1, and this is in part responsible for the switch in
metabolism from mitochondrial respiration to glycolysis in can-
cer cells. Considerable studies have pointed to theWarburg effect,
also termed aerobic glycolysis, as the major adaptive response of
cancer cells, but mitochondrial metabolism and mitochondrial
dynamics are also starting to be recognized as important adaptive
strategies of cancer cells (2). Mitochondria are critical organelles
that regulate both metabolism and cell death. They are dynamic
organelles that continuously undergo fission and fusion during
cell growth (3, 4). Under stress conditions, such as nutrient deple-
tion or hypoxia, mitochondria either fragment or are degraded by
HIF-dependent mitophagy (mitochondrial removal by au-
tophagy) (5) or hyperfuse together to form elongated or rounded
structures that optimize ATP production and promote cell sur-
vival (6–11).
We reported previously that certain cell lines exposed to hyp-
oxia contained enlarged mitochondria (6). We found that the
mechanism was HIF-1 and Bcl-2/adenovirus E1B 19-kDa inter-
acting protein 3 (BNIP3/BNIP3L) dependent but that it was inde-
pendent of mitophagy. In addition, the hypoxic cells were more
resistant to stimulated cell death than normoxic cells (12). Fur-
thermore, we reported that the mitochondrial outer membrane
protein voltage-dependent anion channel 1 (VDAC1) was post-
translationally cleaved at the C terminus in these cells in a HIF-1-
dependent manner and in human lung adenocarcinoma tissue
(12). VDACmediates the transport of ions and small metabolites,
such as ADP/ATP, from and intomitochondria (13). Threemam-
malian isoforms of VDAC exist in eukaryotic cells. VDACs bind
hexokinase, the first enzyme of the glycolytic pathway, and in so
doing provide ATP for conversion of glucose to glucose-6-phos-
phate. VDACs also play a key role in apoptosis through Ca2
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regulation of VDAC1 expression and binding of antiapoptotic
proteins of the Bcl-2 family (14, 15).
The TP53 transcription factor plays an important role in the
response to and regulation ofmetabolic stress in cancer (16, 17). It
is known that a TP53-inducible protein,Mieap (also referred to as
Spata18) (18), controlsmitochondrial quality through interaction
with the HIF-1-inducible protein BNIP3 (19). In addition, Mieap
has been proposed to induce the accumulation of lysosomal pro-
teins within mitochondria by way of repairing damaged mito-
chondria (20).
In the present study, we investigated further the mechanism
behind the hypoxic regulation of the truncation of VDAC1. We
propose that enlarged hypoxic mitochondria make fusional con-
tact with late endolysosomes through TP53-induced Mieap in
promoting cell survival. Furthermore, we report that VDAC1 is
cleaved at loop 14 by the endolysosomal protease asparagine en-
dopeptidase (also termed legumain). Intimate contact between
mitochondria and vacuoles has been described only in Saccharo-
myces cerevisiae yeast (21, 22) and in erythroid cells (23). This
cross talk between organelles was found to regulate lipid trans-
port, cellularmetabolism, and iron transport.We now show that a
spatial and functional interorganellar connection also exists in
eukaryotes, both in cells in culture and in lung adenocarcinomas
of patients. We propose, finally, that VDAC posttranslational
modificationmarksmitochondria for protection frommitophagy
and reflects a survival strategy of hypoxic cancer cells in vitro and
in vivo in patients.
MATERIALS AND METHODS
Cells and hypoxic conditions. Cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM; Gibco-BRL) supplemented with 5 or 10% in-
activated fetal bovine serum, as appropriate.M. van deWetering provided
the LS174 cells. p53/ and p53/mouse embryonic fibroblasts (MEFs)
were provided by P. Roux. An Invivo2 200 anaerobic workstation
(Ruskinn Technology Biotrace International Plc) set at 1% O2, 94% N2,
and 5% CO2 was used for hypoxic incubation. HeLa cells were incubated
for 48 h in hypoxia, while the other cells, unless otherwise indicated, were
incubated for 72 h.
Pharmacological inhibitors and chemicals. Bafilomycin A1was pur-
chased from Calbiochem. Brefeldin A, chloroquine diphosphate, LY-
294002, 3-methyladenine, rapamycin, valinomycin, pepstatin A, E64d,
rotenone antimycin, oligomycin, and trifluorocarbonylcyanide phenyl-
hydrazone (FCCP) were from Sigma.
Transfection of plasmids and RNA interference. The plasmid carry-
ing yellow fluorescent protein (YFP)-tagged Parkin (YFP-Parkin) was
purchased fromAddgene (24). The 21-nucleotide RNAswere synthesized
by Eurogentec or OriGene. HeLa or LS174 cells were transfected with 40
or 100 nMsmall interferingRNA (siRNA) twice at an interval of 24 h prior
to normoxia or hypoxia, as described previously (6).
siRNA sequences were as follows: siRNA against VDAC1 (forward),
5=-GAUACACUCAGACUCUAAA-3=; siRNA against VDAC1 3= un-
translated region (forward), 5=-CUCCAGGUUAAAGUUGAUUCA-3=;
siRNA against VDAC2 (forward), 5=-GAAGAUUUGGCCUUAAUAU-
3=; siRNA against TP53#1 (forward), 5=-GACUCCAGUGGUAAUC
UAC-3=; siRNA against TP53#3 (forward), 5=-UAUGGCGGGAGGUAG
ACUG-3=; siRNA against autophagy-related gene 5 (ATG5)/ATG6/ATG7/be-
clin, the sequences were described previously (25); siRNA against ATG4B
(forward), 5=-CUGAAGAUGACUUCAAUGA-3=; siRNA against Lamp2
(forward), 5=-GAAAAUGCCACUUGCCUUU-3=; siRNA against
Mieap#1 (forward), 5=-GUAGCAGUGACUUAAGGCUAAG-3=; siRNA
against Mieap#2 (forward), 5=-GGUGCAGGGACAACUCUUUGGG-3=;
siRNA against Mieap#3 (forward), 5=-GAGAUAUGUUGCAUUGCCUU
UGC-5=; siRNA againstMieap#4 (forward), 5=-GCACUAUCUGCCUAG
GUAACUGC-5=; siRNA against Lamp1A (forward), 5=-AGAAAUGCAA
CACGUUA-5=; siRNA against Lamp2A (forward), 5=-GCUGUGCGGUC
UUAUGCAU-5=; siRNA against BNIP3 and B3L, the sequences were
described previously (25); and siRNA against mitofusin 1 (Mfn1), the se-
quence was previously described (12). Three siRNAs against asparagine en-
dopeptidase and a scrambled siRNA were purchased from Origene; the se-
quences were not disclosed.
Caspase activation and cell death induced by STS. Quantification of
caspase 3/7 activity was done using a luciferin/luciferase-based assay
(Caspase-Glo 3/7 kit; Promega) according to the manufacturer’s instruc-
tions. Tests under each condition were performed eight times, and the
entire experiment was performed three times. Significant differences (P
0.005) were based on the Student t test. Staurosporine (STS; 1 M) was
added 4 h prior to the assay for caspase 3/7 activity. Cell death was also
determined by trypan blue exclusion and confirmed with an Adam cell
counter.
Transmission electron microscopy. Cells were fixed in situwith 1.6%
glutaraldehyde in 0.1Mphosphate buffer at room temperature for at least
1 h and then conserved at 4°C. Samples were rinsed in the same buffer and
then postfixedwith 1%osmium tetroxide and 1%potassium ferrocyanide
in 0.1 M cacodylate buffer for 1 h at room temperature to enhance the
staining of cytoplasmicmembranes. Cells were rinsedwith distilled water,
dehydrated in alcohol, and embedded in epoxy resin. Embedded samples
were then processed for ultrathin sectioning and observed with a
JEM1400 transmission electron microscope (JEOL, Tokyo, Japan)
equipped with a Morada charge-coupled-device camera (Olympus SIS,
Rungis, France).
For immunogold staining, cells were fixed with 4% paraformaldehyde
and 0.1% glutaraldehyde in 0.1 M phosphate buffer (PB; pH 7.4) for 2 h
and were processed for ultracryomicrotomy according to a slightly mod-
ified Tokuyasu method. In brief, a cell suspension was spun down in 10%
gelatin. After immersion in 2.3 M sucrose (in pH 7.4 0.1 M PB) overnight
at 4°C, the samples were rapidly frozen in liquid nitrogen. Ultrathin (70-
nm-thick) cryosectionswere preparedwith an ultracryomicrotome (Leica
EMFCS, Austria) andmounted on Formvar-coated nickel grids (Electron
Microscopy Sciences, Fort Washington, PA). Immunostaining was per-
formed with an automated immunogold labeling system (Leica EM IGL)
as follows: the grids were incubated successively in phosphate-buffered
saline (PBS) containing 50mMNH4Cl (2 times for 5min each time), PBS
containing 1% bovine serum albumin (BSA; 2 times for 5min each time),
PBS containing the relevant primary antibody (for VDAC1, antibody
ab15895; for Lamp1, antibody ab25630; for Lamp2, antibody ab25631 [all
antibodies were from Abcam]) in 1% BSA for 1 h, PBS containing 0.1%
BSA (3 times for 5 min each time), PBS containing 1% BSA and 15-nm
colloidal gold-conjugated protein AG (Cell Microscopy Core, University
Medical Center, Utrecht, TheNetherlands), PBS containing 0.1%BSA for
5 min, and PBS twice for 5 min each time. Lastly, the samples were fixed
for 10 min with 1% glutaraldehyde, rinsed in distilled water, and con-
trasted with amixture ofmethylcellulose-sucrose and 0.3%uranyl acetate
on ice. After drying in air, the sections were examined under a JEOL 1400
transmission electron microscope. For Lamp1 and Lamp2 staining with
mouse primary antibodies, an additional step was added before the incu-
bation with the colloidal gold protein AG: the grids were incubated with a
secondary rabbit antibody raised against mouse IgG (antibody Z0259;
Dako).
Respirometry and extracellular acidification. The cellular oxygen
consumption rate (OCR) and extracellular acidification rate (ECAR)were
obtained using a Seahorse XF96 extracellular flux analyzer from Seahorse
Bioscience (North Billerica, MA). The final concentrations of the agents
are given in the appropriate figure legends. The experiments were per-
formed according to the manufacturer’s instructions. Protein standard-
ization was performed after each experiment, and no noticeable differ-
ences in protein concentration and cell phenotype were detected.
Immunoblotting. For immunoblotting, cells were lysed in 1.5 SDS
buffer and the protein concentration was determined using a bicin-
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choninic acid assay. Fortymicrograms of protein fromwhole-cell extracts
was resolved by SDS-PAGE and transferred onto a polyvinylidene diflu-
oridemembrane (Millipore). Themembranes were blocked in 5% nonfat
milk in TN buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl) and incu-
bated in the presence of the primary antibody and then secondary anti-
bodies in 5% nonfat milk in TN buffer. The rabbit polyclonal antibody to
the central regions of VDAC1 was purchased from Abcam (antibody
ab15895). Rabbit polyclonal anti-HIF-1 antibody (antiserum 2087) was
produced and characterized in our laboratory (26). Anti-phospho-TP53
(Ser15) (Cell Signaling Technology, Boston, MA), anti-transactivation
TP73 (anti-TA TP73) (catalog number IMG-246; Imgenex), anti-Mieap
(Novus Biologicals, Cambridge, United Kingdom), anti-p62 (Sigma-Al-
drich, St. Louis, MO), and anti-TP63 and anti-beclin 1 (Novus Biological,
Cambridge, United Kingdom) were obtained from the indicated manu-
facturers. Mouse anti--tubulin and -actin were from Sigma, and anti-
asparaginyl endopeptidase (anti-AEP; EC 3.4.22.34; Sigma Prestige) was
from Sigma. Anti-BNIP3 and anti-BNIP3L were described previously
(25). After washing in TN buffer containing 1% Triton X-100 and then in
TN buffer, immunoreactive bands were visualized with an ECL system
(AmershamBiosciences). The enhanced chemiluminescence (ECL) signal
for -tubulin or -actin was used as a loading control.
Pulldown with BNIP3 and mass spectrometry. HepG2 cells with sta-
ble expression of the tetracycline repressor (pcDNA6/TR; Life Technolo-
gies) were transiently transfected with the pcDNA 4/TO plasmid express-
ing the HaloTag-BNIP3 fusion protein using the Lipofectamine reagent.
At 24 h after the transfection, the cells were then incubated in the presence
of 1 g/ml tetracycline to induce HaloTag-BNIP3 expression and incu-
bated without or with etoposide 50 M in hypoxia (1% O2) for 16 h.
Protein pulldown was performed according to the HaloTag mamma-
lian pulldown system protocol (Promega). Tobacco etch virus protease
cleavage (30 units of Protev proteases in 50l of Protev cleavage buffer for
1 h at 25°C) was used to isolate the entire complex, including the bait
protein BNIP3 fused to the HaloTag. After elution, proteins were boiled
for 5 min with 3-[3-(1,1-bisalkyloxyethyl)pyridin-1-yl]propane-1-sulfo-
nate (PPS; final concentration, 0.8%; silent surfactant; Protein Discov-
ery), reduced for 30 min at 50°C with dithiothreitol (5 mM), and then
alkylated for 30 min in the dark using iodoacetamide (15 mM). Samples
were then digested overnight at 37°C with trypsin (Trypsin Gold, mass
spectrometry [MS] grade; Promega). Prior to MS, samples were acidified
with 1 l of 12 N HCl, and PPS detergent was hydrolyzed after a 45-min
incubation at 37°C, followed by centrifugation (10 min, 16,000  g) at
4°C. Peptides were analyzed using a nano-liquid chromatography (LC)-
electrospray ionization-tandem MS maXis Impact ultra-high-resolution
time of flight system (Bruker, Bremen,Germany) coupledwith a nano-LC
UltiMate 3000 system (Thermo). The digests were separated by reverse-
phase liquid chromatography using a reverse-phase Thermo column (75
m by 250 mm; Acclaim PepMap 100 C18) in an Ultimate 3000 liquid
chromatography system.Mobile phase A was 95%water, 5% acetonitrile,
and 0.1% formic acid. Mobile phase B was 20%water, 79.9% acetonitrile,
and 0.1% formic acid. The digest (8 l) was injected, and the organic
content of the mobile phase was increased linearly from 5%mobile phase
to 40%mobile phase B in 85 min and from 40%mobile phase B to 100%
mobile phase B in 10min. The column effluentwas connected to aCaptive
Spray apparatus (Bruker). In the survey scan, MS spectra were acquired
for 0.5 s in themass-to-charge (m/z) ratio range of from 50 and 2,200. The
15 most intense peptide ions with charges of 2 or 3 were sequenced.
The collision-induced dissociation (CID) energy was automatically set
according to the m/z ratio and charge state of the precursor ion. The
maXis andThermo systemswere piloted byCompassHyStar (version 3.2)
software (Bruker).
Peak lists were created using the DataAnalysis (version 4.0) program
(Bruker) and saved as an MGF file for use with the ProteinScape (version
3.1) program (Bruker) and Mascot (version 2.4) as the search engine
(Matrix Science). Enzyme specificity was set to trypsin, and themaximum
number of missed cleavages per peptide was set to 1. Carbamidomethyla-
tion, oxidation ofmethionine, andGln–pyro-Gluwere allowed as variable
modifications. The mass tolerance for the monoisotopic peptide window
was 7 ppm, and theMS/MS tolerancewindowwas set to 0.05Da. The peak
lists were searched against the NCBInr mammalian database (entries
02122011 and 2075986) with an automatic decoy database search. Scaf-
fold (version 4.3) program (Proteome Software) was used to validate the
MS/MS-based peptide and protein identifications. Peptide identifications
were accepted if they could be established at a greater than 95% probabil-
ity by use of the PeptideProphet algorithm (27) with Scaffold delta-iden-
tified peptides. Protein identifications were accepted if they could be es-
tablished at greater than 5.0% probability to achieve a false discovery rate
(FDR) of less than 1.0% and contained at least 2 identified peptides. Pro-
tein probabilities were assigned with the ProteinProphet algorithm (28).
Mass spectrometry of VDAC1 and VDAC1-C. Imperial blue-
stained bands excised from SDS-polyacrylamide gels, corresponding to
full-length VDAC1 from normoxic and hypoxic cell mitochondria and a
truncated form of VDAC1 (VDAC1-	C) from hypoxic HeLa cell mito-
chondria, were digested in gel with trypsin, as recently described (29). For
LC-MS analysis, peptides were separated on a reverse-phase LC column
(75mby 20 cm) packed in-house with C18 resin (Magic C18 AQ; particle
size, 3 m; Michrom BioResources, Auburn, CA) using a linear gradient
from 95% solvent A (98%water, 2% acetonitrile, 0.15% formic acid) and
5% solvent B (98% acetonitrile, 2% water, 0.15% formic acid) to 30%
solvent B over 40 min at a flow rate of 0.2 l/min. Each survey scan
acquired in the Orbitrap analyzer at 60,000 full width at half maximum
was followed by 20MS/MS scans of themost intense precursor ions in the
linear ion trap with dynamic exclusion enabled for 20 s. Charge state
screening was employed to select for ions with at least two charges and
rejecting ions with an undetermined charge state. The normalized colli-
sion energy was set to 32%, and one microscan was acquired for each
spectrum. The ion accumulation time was set to 300 ms (MS) and 50 ms
(MS/MS).
For peptide identification, raw files were converted to MGF format
using theMassMatrix conversion tool (version 3.9; www.massmatrix.org)
and searched against a decoy human Swiss-Prot database consisting of
forward and reverse protein sequences (download date, 16 May 2012)
containing VDAC and known contaminants, resulting in a total of 41,251
protein sequences using the Mascot (version 2.4) search engine (Matrix
Science). The search parameters were set as follows; semitryptic specificity
was required, up to twomissed cleavages were allowed, carbamidomethyl
of cysteine residues was set as fixed, oxidation of methionine residues was
set as a variable modification, the precursor mass tolerance was 10 ppm,
and the fragmentmass tolerance for CID tandemmass spectra was 0.6Da.
After importing the data to Scaffold software (version 4.2.1; Proteome
Software), the FDR was set to 1% for peptide identifications by the
Scaffold local FDR algorithm.
For peptide quantification, raw files were loaded into the Skyline soft-
ware tool (version 2.4) to generate extracted ion chromatograms and
determine peak abundances for all identified peptide ions generated by
the VDAC protein. All integrated peaks/transitions were manually in-
spected and validated, if required.
SDS-PAGE of recombinant AEP incubated with recombinant
VDAC1 or hypoxic HeLa cell mitochondria. Recombinant VDAC1 ex-
pressed in Escherichia coli was reconstituted into eitherN,N-dimethyldo-
decylamine N-oxide (LDAO) micelles or large unilamellar vesicles
(LUVs) following published protocols (30, 31) and incubated with low-
pH-autoactivated (0.1M citrate buffer, pH 5.5) recombinant AEP (rAEP)
(32) for 180 min at room temperature. Samples of inactive or low-pH-
autoactivated rAEP and recombinant VDAC1, together with samples of
active AEP incubated with VDAC1 LUVs or LDAO micelles, were ana-
lyzed by SDS-PAGE. Gels were stained with Coomassie blue. Mitochon-
dria from HeLa cells were isolated using a mitochondrion isolation kit
(MitoSciences). Mitochondria were resuspended in 0.1 M citrate buffer
(pH 5.5), and rAEP was added. AEP-expressing plasmid pcDNA3.1 was
used for overexpression of AEP.
Endolysosomal Modiﬁcation of Hypoxic Mitochondria
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FIG 1 Truncation of VDAC1 requires wild-type TP53. (A) HeLa cells were treated for 24 h with dimethyl-oxalylglycine, and cell lysates were analyzed by
immunoblotting for HIF-1, VDAC, or -actin. (B) Wild-type (wt) or TP53 null or mutated cells were analyzed by immunoblotting for VDAC, HSP90, or
-actin. (C) (Top) LS174 cells were transfected with control siRNA (siCtl) or TP53-specific siRNA (siTP53; 40 nM) in normoxia (Nx) or hypoxia (Hx), and cell
lysates were analyzed by immunoblotting for HIF-1, TP53, phospho-TP53 (P-TP53), VDAC, or -tubulin. (Bottom) Quantification of TP53 is shown. (D) wt
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Patients and tissue sample preparation.Tenpatientswhounderwent
surgery for lung adenocarcinoma betweenMay 2007 andMay 2010 at the
Pasteur Hospital (Department of Thoracic Surgery, CHU of Nice, Nice,
France) were selected. The patients received the necessary information
concerning the study, and consent was obtained. The study obtained the
approval of the Ethics Committee of the CHU of Nice. The main clinical
and histopathological data are summarized in Table S2 in the supplemen-
tal material. Morphological classification of the tumors was assigned ac-
cording to the WHO criteria (33). The tumors were staged according to
the international tumor-node-metastasis system (34). Tumors with at
least 80% tumor cells were selected. Protein and microRNA were ex-
tracted from the same tissue sample using an AllPrep DNA/RNA/protein
kit according to the protocol described by the manufacturer (Qiagen).
Statistics. All values are the means
 standard deviations (SDs). Sig-
nificant differences are based on the Student t test, and P values are indi-
cated in the figures. All statistical tests were two-sided, and P values of
0.05 indicated statistical significance.
RESULTS
Cleavage of VDAC1 is regulated by TP53.Wepreviously demon-
strated that in hypoxia (1%O2 for 48 to 72 h) certain cell lines (the
CCL39, LS174, A549, 786-O, HeLa, and MEF cell lines) showed
enlarged functional mitochondria and enhanced resistance to
staurosporine (STS)-induced apoptosis, while others (the PC3,
SkMel, MDA-MB, and HT29 cell lines) showed a normal tubular
mitochondrial network and were sensitive to apoptosis (6). More
recently, we showed that hypoxic cells with enlarged mitochon-
dria contained a truncated form of VDAC1 (VDAC1-	C), the
production of which was HIF-1 dependent (12).We now confirm
the HIF-1 dependence of VDAC processing with the pharmaco-
logical inhibitor dimethyl-oxalylglycine (DMOG), which stabi-
lizes HIF-1 in normoxia through inhibition of HIF dioxygenases
(Fig. 1A). In contrast to the findings in hypoxia, DMOG treatment
led to more rapid VDAC1 processing (24 versus 48 h). However,
unlike the findings in hypoxia, high concentrations of DMOG (1
mM) induced cell death. So, subsequent experiments were done
under the more physiological condition of hypoxia. VDAC1-	C
was not detected or onlyminimally detected in normoxia in any of
the cell lines tested (Fig. 1B). We now note that the cells with
enlarged mitochondria were TP53 wild type, while the other cell
lines were either TP53 null or mutant (Fig. 1B). Some of these cell
lines also showed increased expression in hypoxia. We showed
that in LS174 cells transfected with TP53-specific siRNA, the level
of VDAC1-	C diminished (Fig. 1C). The amount of full-length
VDAC1was substantially increased, which further confirmed that
VDAC1-	C is a product of full-length VDAC1, as we previously
demonstrated (12). In addition, we examined mouse embryonic
fibroblasts either wild type or null for TP53 and noted that the
former showed VDAC1-	C in hypoxia, while the latter did not
(Fig. 1D). Since we found previously that the formation of
VDAC1-	C is associated with increased resistance to STS-in-
duced apoptosis (12), we examined if silencing of TP53 modified
the level of resistance. Indeed, in hypoxia, LS174 cells transfected
with TP53-specific siRNA showed more STS-induced cell death
than control transfected cells challenged with STS (Fig. 1E).
Knowing thatHeLa cells arewild type forTP53 but that the level of
TP53 is low due to degradation by the human papillomavirus E6
protein (35), as confirmed here (see Fig. S1A in the supplemental
material), we questioned further the involvement of TP53. In
mammals, the TP53 family comprises two additional proteins,
TP63 and TP73, that activate TP53 target genes (36). So, we hy-
pothesized that in HeLa cells these proteins might substitute for
TP53 and thereby promote VDAC cleavage and protection from
induced apoptosis. However, TP63 was present at only very low
levels (see Fig. S1B in the supplementalmaterial) and TP63 siRNA
(DeltaNp63- and Tap63-specific siRNAs) did notmodify the level
of VDAC1-	C (see Fig. S1C in the supplemental material) in hy-
poxic HeLa cells. In contrast, siRNA against TP73 diminished the
level of VDAC1-	C (see Fig. S1D in the supplemental material)
and enhanced sensitivity to STS-induced cell death (Fig. 1F) in
HeLa cells. So, TP73 was able to substitute for TP53 in HeLa cells.
We also noted that the LS174 cells were mutated in TP73 (37),
which further confirmed the involvement of TP53 in truncation,
as described above. Silencing of TP53 or of HIF-1 in hypoxic
LS174 cells diminished survival, and silencing of the two together
further diminished survival in the presence of STS (Fig. 1G).
TP53 regulation of VDAC1 cleavage occurs through mito-
chondrial Mieap and is dependent on the endolysosomal pH. It
is known that a TP53-inducible protein, Mieap (18), controls mi-
tochondrial quality (19). Using TP53-specific siRNA, we con-
firmed, as published previously (19), thatMieap is TP53 inducible
(Fig. 2A). Silencing of Mieap expression (see Fig. S1E in the sup-
plemental material) diminished the truncation of VDAC1 (Fig.
2B) and increased STS-induced cell death in hypoxia (Fig. 2C).
HeLa cells express only TP73, while LS174 cells express only TP53,
yet a similar level of expression of Mieap was noted (Fig. 2A; see
also Fig. S1E in the supplemental material). This suggests ex-
changeable gene activation by TP53/TP73. These results demon-
strate that TP53 regulates VDAC1 truncation via Mieap. In fact,
Mieap has been proposed to induce accumulation of lysosomal
proteins within mitochondria by way of repairing damagedmito-
chondria (20). However, we were unable to detect the lysosomal
membrane protein Lamp1 or Lamp2 in mitochondria by immu-
noelectron microscopy (see Fig. S2A to C in the supplemental
material), and siRNA against Lamp1 and/or Lamp2 did not mod-
ify the truncation of VDAC1 (see Fig. S2D in the supplemental
material). Instead, we questioned whether lysosomes could con-
tribute to mitochondrial quality control or metabolism by acting
from the outside of the mitochondria rather than from the inside.
HeLa cells were first incubated in hypoxia in the presence of agents
that increase the lysosomal pH, including bafilomycin A1, an in-
hibitor of lysosomal V-ATPase, as well as chloroquine andNH4Cl,
which are weak bases. All these compounds efficiently inhibited
the cleavage of VDAC1 to VDAC1-	C, confirming an important
lysosomal function in VDAC1 cleavage (Fig. 2D; see also Fig. S2E
in the supplemental material). Treatment with bafilomycin A1 or
or TP53 nullMEFs in hypoxia were analyzed by immunoblotting. (E) LS174 cells were transfectedwith either control siRNAor TP53-specific siRNA in normoxia
or hypoxia and challenged or not challenged with STS (1 mM) for 4 h or not challenged. Apoptosis was evaluated with caspase 3/7 (three independent
experiments were performed in quadruplicate, and values are means
 SDs). RLU, relative light units. (F) HeLa cells were transfected with either control siRNA
or TP73 siRNA in normoxia or hypoxia and analyzed by immunoblotting. (G) LS174 cells were transfected with control siRNA (siCont) or siRNA against TP53,
HIF-1 (siHIF-1), or both TP53 andHIF-1 and incubated in hypoxia. Cells were then challenged or not challengedwith STS (1mM) for 4 h or not challenged.
Apoptosis was evaluated with an Adam system (independent experiments were performed in triplicate, and values are means
 SDs).
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chloroquine was also associated with an increase in drug-induced
cell death (Fig. 2E).
However, as bafilomycin A1 and chloroquine are also known
to inhibit thematuration and degradation of autophagic vacuoles,
as confirmed here (Fig. 2F; see also Fig. S2F in the supplemental
material), and as hypoxia also induces autophagy throughHIF-1
stabilization, as seen from the enhanced expression of p62/
SQSTM1, the autophagic adaptor protein (see Fig. S3A in the
FIG 2 Truncation of VDAC1 requires TP53-inducedMieap and an increase in endosomal-lysosomal pH-inhibited VDAC1-	C formation. (A) LS174 cells were
transfectedwith either control siRNA (siCtl) or TP53-specific siRNA (siTP53#3; one of three TP53-specific siRNAs; 40 nM), incubated in hypoxia (Hx), and lysed
for analysis by immunoblotting. (B)HeLa cells were transfected with either control siRNA or two differentMieap-specific siRNAs (siMieap#1 and siMieap#2; 40
nM), incubated in hypoxia, and lysed for analysis by immunoblotting. (C) HeLa cells were transfected with control siRNA orMieap-specific siRNA (siMieap; 40
nM), incubated in normoxia (Nx) or hypoxia, and then challenged or not challengedwith STS (1mM) for 4 h. Apoptosis from caspase 3/7 activity was evaluated.
Data are from at least three independent experiments performed in quadruplicate, and values are means
 SDs. (D) HeLa cells were incubated in normoxia or
hypoxia in the absence or presence of bafilomycin A1 (Baf) or chloroquine (CQ) at the indicated concentrations. The formation of VDAC1-	Cwas detected by
immunoblotting. (E)HeLa cells were incubated in normoxia or hypoxia without or with bafilomycin A1 (0.03mM) or chloroquine (17mM) and then incubated
without or with STS (1 mM) for 24 h. Cell death was evaluated by trypan blue exclusion. (F) Electron micrographs of hypoxic HeLa cells incubated without
(control) or with bafilomycin A1 (0.03 M). AV, autophagic vacuole.
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supplemental material), and BNIP3/BNIP3L(NIX) expression (5,
25), we investigated the role of autophagy in VDAC1 processing.
However, known inhibitors (LY-294002 and 3-methyladenine) or
activators (rapamycin) of autophagy (38) did not modify the pro-
cessing ofVDAC1 (see Fig. S3B in the supplementalmaterial). The
inhibitors pepstatin A and E64d (38) did not and did inhibit trun-
cation, respectively (see Fig. S3C in the supplementalmaterial). In
addition, siRNA against autophagy-related gene (ATG) proteins,
key components of the autophagic machinery, did not modify
VDAC processing but did lower the expression of p62 (see Fig.
S3D in the supplemental material). Although we have already
demonstrated in HeLa cells that hypoxia did not induce mitophagy,
weexamined further thepossible implicationofmitophagy,using the
model of trifluorocarbonylcyanide phenylhydrazone (FCCP)-depo-
larized mitochondria. Exogenous overexpression of YFP-Parkin in
HeLacells (seeFig. S3E in the supplementalmaterial)withoutorwith
FIG 3 BNIP3 and mitochondrial fusion are implicated in VDAC1 truncation. (A) HeLa cells were transfected with a control siRNA (siCtl), BNIP3-specific
siRNA (siB3; 40 nM), BNIP3L-specific siRNA (siB3L; 40 nM), or siRNAs against both BNIP3 and BNIP3L (siB3/siB3L; 40 nM each), incubated in hypoxia (Hx),
and lysed for analysis by immunoblotting for the indicated proteins. (B) HeLa cells were transfected with a control siRNA or BNIP3- or BNIP3L-specific siRNA,
and the oxygen consumption rate (OCR) was evaluated with a Seahorse apparatus. Glucose (Glu.; 10 mM), oligomycin (Oligo.; 1 M), FCCP (1 M), and
rotenone (Rot.; 1 M) plus antimycin (AA; 1 M) were injected at the indicated times. (C) HeLa cells were transfected with control siRNA or two different
VDAC1-sprecific siRNAs (siVDAC#1 and siVDAC#2), and the oxygen consumption ratewas evaluatedwith a Seahorse apparatus. Glucose (10mM), oligomycin
(1 M), FCCP (1 M), and rotenone (1 M) plus antimycin (1 M) were injected at the indicated times. (D) Valinomycin was added to HeLa cells and then
placed in hypoxia, and lysates were analyzed by immunoblotting. (E) HeLa cells were transfected with control siRNA or Mfn1-specific siRNA (siMfn1#1) and
incubated in hypoxia, and lysates were analyzed by immunoblotting. (F) HepG2 cells expressing a tetracycline-inducible HaloTag-BNIP3 fusion protein were
incubated in hypoxia (16 h) and then incubated without or with etoposide (Eto; 50mM). Cell lysates were pulled down using theHaloTagmammalian pulldown
system protocol, and proteins were identified bymass spectrometry. Themajor proteins pulled down are presented for each condition. Results are representative
of those from three experiments. Details concerning the individual proteins are given in Table 1. (G) HeLa cells were incubated in hypoxia without or with
brefeldin A, and cell lysates were analyzed by immunoblotting.
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FCCP, used as previously described (24), did not induce the trunca-
tion of VDAC1 in normoxia (see Fig. S3F in the supplemental mate-
rial). Taken together, these results suggest that lysosomes are impli-
cated in VDAC processing but that the mechanism does not involve
autophagy and/or mitophagy.
Truncation of VDAC1 is dependent on BNIP3 and mito-
chondrial fusion but not on the mitochondrial membrane po-
tential. As Mieap has been reported to interact with BNIP3/
BNIP3L at the mitochondrial outer membrane (19), we
investigated the role of BNIP3 and BNIP3L in VDAC1 truncation.
Using siRNAagainst BNIP3 andBNIP3L (25), we found that these
proteins are necessary for processing of VDAC1 into VDAC1-	C
(Fig. 3A). In addition, BNIP3L-specific siRNA diminished oxida-
tive phosphorylation (OXPHOS) (Fig. 3B) to a level similar to that
obtained with VDAC1-specific siRNA (Fig. 3C), whereas BNIP3-
specific siRNA significantly reduced OXPHOS. As we previously
showed that enlarged mitochondria resulted from hyperfusion
through BNIP3 and BNIP3L (6), we first tested valinomycin, a K
ionophore that uncouples OXPHOS, as confirmed here (see Fig.
S4 in the supplemental material), and prevents the fusion of mi-
tochondria (39). Valinomycin inhibited truncation (Fig. 3D),
while neither oligomycin (see Fig. S5A in the supplemental mate-
rial) nor FCCP (see Fig. S5B and C in the supplemental material)
affected truncation in hypoxic cells. However, valinomycin-
treated cells partially maintained glycolysis in both normoxia and
hypoxia, thereby allowing cells to survive. These results suggest
that mitochondrial fusion is a prerequisite to VDAC1 truncation.
In addition, siRNA against mitofusin 1 (Mfn1), a protein that we
previously showed is essential for hypoxic mitochondrial hyper-
fusion (6), partially silenced Mfn1 and diminished the level of
VDAC1-	C (Fig. 3E).
To further examine the role of BNIP3, we used the HaloTag
mammalian pulldown system protocol with BNIP3 as the bait in
HepG2 cells. Indeed, these liver-derived cells, which are enriched
in mitochondria, presented high levels of VDAC1 and VDAC1-
	C, which were even upregulated in hypoxia (see Fig. S1A in the
supplemental material). We identified by mass spectrometry the
binding of several proteins, including clathrin, a structural protein
involved in vesicle trafficking (40), in hypoxic HepG2 cells. When
apoptosis was induced with etoposide in hypoxic cells, which we
previously found induced the same level of cell death as STS (12),
BNIP3 also pulled down the lysosomal protein Lamp1 (Fig. 3F;
Table 1), which further implicates lysosome involvement in resis-
tance to apoptosis in hypoxia. However, Mieap was not pulled
down, suggesting that BNIP3 and Mieap did not bind directly,
which contrasts with the findings of a previous report (19). Since
pulldown experiments showed that clathrin bound BNIP3 in hy-
poxic cells and that clathrin is involved in vesicle trafficking, the
effect of brefeldinA, an inhibitor of transport of secretory proteins
from the endoplasmic reticulum to the Golgi apparatus, was ex-
amined. Brefeldin A inhibited VDAC1-	C formation (Fig. 3G),
which further suggests that secretory vesicles are involved in trun-
cation.
Mitochondria make contact with endolysosomal compart-
ments in hypoxia. We observed on electron micrographs of hy-
poxic LS174 cells that hyperfused mitochondria make contact
with late endosomes and lysosomes (Fig. 4A). The membranes of
mitochondria and endolysosomes showed fusional contact, where
some late endosomes puckered up to mitochondria (arrow) or
pinched into mitochondria (arrowhead) (Fig. 4A, inset). Al-
though it was difficult to quantify, we frequently noted an inter-
action between these organelles (Fig. 4B to D) and confirmed the
identity of mitochondria by performing immunogold labeling of
VDAC (Fig. 4E). In addition, we did not observe enlarged mito-
chondria in the proximity of autolysosomes. So, these data further
support a process other than mitophagy in the transformation of
mitochondria in hypoxia.
VDAC1 is C-terminally truncated at asparagine 214 by en-
dolysosomal asparagine endopeptidase. Mass spectrometric
analyses showed that the site of cleavage in VDAC1 was at aspar-
agine 214 (major cleavage site) and glycine 213 (minor cleavage
site) (Fig. 5A and B; see also Fig. S6A in the supplemental mate-
rial). These residues are located in loop 14, which is accessible to
the cytosol. The asparagine residue is not conserved in VDAC2 or
VDAC3, but the glycine is (Fig. 5B), and these residues are highly
conserved in VDAC1 proteins ranging from Xenopus to humans
(see Fig. S6B in the supplementalmaterial). Sincewe suspected the
involvement of late endosomes and lysosomes in truncation, we
screened siRNAs against some endolysosomal enzymes and found
that transfection of asparaginyl endopeptidase (AEP)-specific
siRNA lowered the level of expression of AEP and the amount of
VDAC1-	C (Fig. 5C). We did not detect any difference in the
TABLE 1 Details of major proteins pulled down with a HaloTag-BNIP3 fusion protein expressed in hypoxic HepG2 cells challenged or not
challenged with etoposidea
Accession no. Protein (source species) Function Molecular size (kDa)
gi 17064083 p25 (Homo sapiens) A component of the cytoplasmic dynein motor machinery involved in
minus-end-directed transport
25.0
gi 4505773 Prohibitin (Homo sapiens) Plays a role in human cellular senescence and tumor suppression 29.8
gi 30353925 Clathrin protein (Homo sapiens) Major protein component of the cytoplasmic face of intracellular
organelles, called coated vesicles and coated pits; these specialized
organelles are involved in the intracellular trafficking of receptors
and endocytosis of a variety of macromolecules
187.8
gi 28386260 Pgmc2 protein (Mus musculus) 23.0
gi 1020320 CDM protein (Homo sapiens) 14.1
gi 39644554 Lamp1 protein (Homo sapiens) Presents carbohydrate ligands to selectins; also implicated in tumor
cell metastasis
33.4
gi 4757900 Calreticulin precursor (Homo sapiens) A multifunctional protein that acts as a major Ca2-binding (storage)
protein in the lumen of the endoplasmic reticulum
48.1
gi 15529966 Transmembrane protein 205 (Homo sapiens) Plays a role in resistance to the chemotherapeutic agent cisplatin 21.2
a HepG2 cells were in hypoxia for 16 h, and etoposide was used at 50 mM. Results are representative of those from three experiments.
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FIG 4 Hypoxic LS147 cells show close interactions between mitochondria and late endosomes and lysosomes. (A) A representative image from an electron
micrograph of an LS174 cell showing an interaction between a mitochondrion (Mito) and a late endosome (LE) showing membrane rupture (arrow) and a late
endosome with a lysosome (Ly) showing membrane rupture (arrowhead; see the inset). (Inset) Enlarged view of a late endosome showing blebbing at the
mitochondrion-late endosome contact site. (B to D) (Left) Representative electronmicrographs of LS174 cells showing the interaction of a mitochondrion with
late endosomes and lysosomes. (Right) Enlarged views of the interaction sites. (E) (Left) Representative electron micrograph of LS174 cells showing immuno-
gold-stained VDAC, allowing detection of mitochondria making contact with a lysosome. (Right) Enlarged view of the contact site.
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FIG 5 Mitochondria-endolysosome contact in hypoxia leads to truncation of VDAC1 at asparagine 214 by the endolysosomal asparagine endopeptidase. (A)
Ratios of the abundance of human VDAC1 (hVDAC1) peptides from the normoxic sample to the abundance from the hypoxic sample. Residue numbers are
indicated together with the peptide amino acid sequence. The y axis displays the decimal logarithm of the relative abundance of a given peptide in normoxia
versus hypoxia. (B) Structure of VDAC1 showing themajor cleavage site of VDAC1C terminal to asparagine 214 (site C) and aminor cleavage site at glycine 213
(site C=). The consensus sequence between humanVDAC1, VDAC2, and VDAC3 at the cleavage site is shown by boldface circles. (C)HeLa cells transfected with
two different AEP-specific siRNAs (siAEP#1 and siAEP#2) incubated in hypoxia (Hx) and analyzed by immunoblotting (Ctl, control; siCtl, scrambled control
siRNA). (D) HeLa cells were transfected with either a control siRNA or asparagine endopeptidase-specific siRNA (siAEP; 100 nM), incubated in normoxia (Nx)
or hypoxia, and challenged with STS (1 mM) for 4 h. Apoptosis was evaluated from the level of caspase 3/7. Data from two independent experiments performed
in quadruplicate are given asmeans
 SDs. (E) rAEPwas activated by low pH and incubatedwith recombinant VDAC1 (rVDAC1) reconstituted into either large
unilamellar vesicles (LUVs) or N,N-dimethyldodecylamine N-oxide (LDAO) micelles for 180 min at room temperature. The samples were analyzed by
SDS-PAGE.Mk, molecular mass marker; rAEP inact., inactive rAEP; rAEP act., pH-activated rAEP. (F) Autoactivated rAEP was added tomitochondria isolated
from normoxic HeLa cells, and the mixture was incubated for 30 min at 37°C. The samples were analyzed by immunoblotting for VDAC.
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FIG 6 Truncated VDAC is present in lysates of lung adenocarcinoma tissue from patients, and tumor tissue sections show a close interaction between
mitochondria and lysosomes. (A) Representative immunoblots of protein extracts of control tissue (lanes C) and tumor tissue (lanes T) from patients’ lungs. (B)
(Top) A representative electron micrograph of a cell from a patient’s lung adenocarcinoma showing the interaction between a mitochondrion (Mito) and
lysosomes (Ly); (bottom) enlarged view of the contact site. (C) A representative electronmicrograph of tumor tissue showing the interaction of amitochondrion
with lysosomes. (D) (Top) A representative electronmicrograph of tumor tissue showing the interaction of amitochondrion with lysosomes; (bottom) enlarged
view of the interaction site.
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expression levels of the AEP proteins in normoxia compared to
hypoxia by immunoblotting. Drug-induced apoptosis was also
higher in hypoxic cells transfected with AEP-specific siRNA (Fig.
5D). Incubation of low-pH-autoactivated recombinant AEP (32)
with recombinant VDAC1 in large unilamellar vesicles led tomin-
imal degradation; however, inmicelles, VDAC1was degraded, but
degradation was substantial (Fig. 5E). Addition of low-pH-auto-
activated recombinant AEP to mitochondria that were isolated
from normoxic cells and that thus contained only full-length
VDAC showed the production of a signal at the level of
VDAC1-	C (Fig. 5F). Incubation of hypoxic mitochondria with
recombinant AEP only minimally increased the amount of the
truncated form of VDAC1, VDAC1-	C (data not shown). This
may suggest that there is some posttranslational modification to
VDAC1 that is required for processing but that not all of the full-
length form is modified and thus remains insensitive to AEP,
though itmay be sensitive to another lysosomal enzyme.Note that
incubation with trypsin did notmodify the ECL profile of samples
of normoxic or hypoxic mitochondria (data not shown). How-
ever, overexpression of AEP in HeLa cells did not result in either
the substantial truncation of VDAC1 in normoxia or an increase
in truncation in hypoxia (see Fig. S6C in the supplemental mate-
rial). Since AEP is normally localized in endolysosomes and active
only at lowpH, thismay suggest that hypoxia-induced local fusion
is a prerequisite to truncation and that the degree of local fusion is
limiting. In addition, the time frame required to obtain VDAC1
processing in hypoxia is relatively long, 48 h inHeLa cells and 72 h
in LS174 cells, which is much longer than the time required to
stabilize HIF-1. We speculate from these results that AEP is re-
sponsible for the major cleavage of VDAC1 during microfusional
contact of intact mitochondria with endolysosomes in hypoxia,
but since we detected two adjacent sites of cleavage, another en-
zyme or partner protein yet to be identified is also required for
efficient truncation.
Truncated VDAC1 is present in tumor tissue from patients
with wild-type TP53 lung adenocarcinomas, and enlarged mito-
chondria made contact with endolysosomes. Using a small co-
hort of 10 patients with lung adenocarcinomas for whom we had
the medical history, we found a correlation between the expres-
sion of phosphorylated-TP53 and cleavage of VDAC1 (Fig. 6A).
However, this needs to be confirmed with a larger cohort. This
would also allow correlation between the levels of the activity of
TP53, the amount of VDAC1 processing, and the activation of
HIF-induced targets. Nonetheless, the findings obtained with this
small cohort allow us to propose the basic principle of cross talk
between mitochondria and lysosomes in higher eukaryotes.
As in our previous study with a cohort of 46 patients with lung
adenocarcinoma (12), VDAC1 truncation tended to be associated
with a higher tumor stage andmore metastatic relapse in an inde-
pendent population of lung adenocarcinomas (Tables 2 and 3).
Enlarged mitochondria in close contact with lysosomes were de-
tected by electron microscopy of tumor sections (Fig. 6B to D).
This was observed in all the patients showing truncated VDAC1.
Even though it was not a rare event, it was difficult to quantify.We
did not confirm that the regions in the tissue were hypoxic. This
would require doing investigations using light and electron mi-
croscopy. Contact between mitochondria and lysosomes was not
found in patients not showing truncated VDAC1. While these
findings are for a small cohort, they do allow us to propose the
basic principle of cross talk between mitochondria and lysosomes
in higher eukaryotes.
DISCUSSION
The tumor suppressor TP53 has been reported to function not
only as a guardian of the genome but also as a guardian of mito-
chondrial integrity and function (2). It regulates both mitophagy
and mitochondrial metabolism through the induction of genes
that regulate, respectively, autophagy and components of the elec-
tron transport chain, glycolysis, and the pentose phosphate path-
way (41). In addition, TP53 has been reported to activate necrosis
by opening the mitochondrial permeability transition pore (42).
Although our results point to the involvement of TP53-induced
Mieap and BNIP3-mediated regulation of the hypoxic processing
of VDAC1, we do not conclude, as suggested previously (19, 20),
that lysosome-like organelles or lysosomal proteins accumulate in
mitochondria. However, the latter studies examined exogenous
overexpression of adenovirus-infectedMieap in normoxia, which
contrasts with the conditions of the present study, which exam-
ined endogenous proteins in hypoxic cells. We also did not find
evidence for the production of mitochondrion-derived vesicles,
which are involved in a pathway for shuttling cargo from mito-
chondria to lysosomes that is an alternative tomitophagy (43, 44).
However, this pathway was followed after short-term oxidative
stress rather than long-term hypoxia, as in our study. Instead, our
results suggest that after long-term hypoxia, late endosomes and
TABLE 2 Characteristics of patients and their tumors and patient
outcomes
Characteristic Value
No. (%) of patients 10 (100)
No. (%) of patients by gender
Female 2 (20)
Male 8 (80)
Median (range) age (yr) at time of surgery 62.7 (38–74)














No. (%) of patients with the following
histology:
Adenocarcinoma 10 (100)
Relapse (locoregional or metastatic) 3 (30)
No. (%) of patients who died 5 (50)
Median (range) length of follow-up (mo) 57.5 (38.4–72.0)
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lysosomes dock onto mitochondria and bring the outer mito-
chondrial membrane proteins into contact with their contents.
This is in agreement with the findings of the study by Gomes et al.,
who found that mitochondrial elongation is not dependent on
autophagosome formation (8). Our data suggest that mitophagy
is not the basis for the mechanism behind VDAC1 processing.
This finding confirmed data from our previous study, in which we
showed that in hypoxia the area occupied bymitochondria, deter-
mined by electron microscopy, was equivalent to or even larger
than that in normoxia and that the mass of mitochondria deter-
mined by fluorescence-activated cell sorter analysis remained
constant (6). So,we propose a novelmechanism inwhich enlarged
mitochondria escape mitophagy and promote metabolic effi-
ciency. Why some mitochondria undergo mitophagy in hypoxia
(5) while others persist is still not clear, but it has been suggested
that it may be simply sterical; that is, elongatedmitochondriamay
not fit into autophagosomes (8).Our results provide an additional
or complementary explanation. We suggest that after long-term
stresses, posttranslational modification of VDAC1 marks mito-
chondria for protection from autophagy andmetabolic efficiency.
Under such stress conditions, cells maximize ATP production to
promote cell survival (6), as do the stress-induced hyperfusedmi-
tochondria of MEFs (10), which also rendered them more resis-
tant to cell death. The cleavage of VDAC1 at residues 213 and 214
would result in a protein without  strands 15 to 19 and probably
a change in conformation, as suggested by our previous results
obtained by immunofluorescence of hypoxic cells with an anti-
VDAC antibody (12). This C-terminal segment of the protein
contains the binding site for -NADH (30), which promotes the
closed state of VDAC1. If the residual 14 strands resided in the
membrane and formed a pore, VDAC1-	Cwould remain consti-
tutively open, allowing optimal efficiency in hypoxia to promote
glycolysis through its binding to hexokinases I and II, which we
previously showed still bind to VDAC1-	C (12). VDAC1-	C re-
constituted into a planar lipid bilayer also interacted with Bcl-xL
and reduced its channel conductance (12). At this stage, we do not
know if the C-terminal fragment of VDAC1 is further degraded or
if it plays a functional role in the mitochondrial membrane.
We showed that VDAC1 is cleaved by AEP (EC 3.4.22.34), a
cysteine proteasemainly located in endolysosomes. AEP plays im-
portant roles in regulation of the immune system (45) and in
cancer (46, 47) and has recently been shown to cleave the protein
tau in Alzheimer’s disease (48, 49). In addition, its expression and
activity are regulated by TP53 (50), and it cleaves peptide bonds
carboxy terminal to asparagine (51). The asparagine residue of
VDAC1 cleaved by AEP is exposed on the cytoplasmic side of the
mitochondria, so this residue could come into contact with the
contents of lysosomes. We suggest that BNIP3 acts as a docking
site for lysosomes. We also observed that drug-induced apoptosis
in hypoxia involves the interaction of BNIP3 with clathrin and
Lamp1.
Finally, in the present study we have provided experimental
evidence supporting the conclusion that cleavage of VDAC1 re-
flects a survival response of hypoxic cells that is the readout of an
interaction between hyperfused mitochondria with endolyso-
somes.We show that this phenomenon exists not only in vitro but
also in vivo in patients with lung adenocarcinomas. This cross talk
between organelles ismediated byTP53-inducedMieap and bind-
ing to hypoxia-induced BNIP3. Further understanding of the
function of cancer cell mitochondria should stimulate investiga-
tion into pharmacological approaches tomodulatemitochondrial
function to design better cancer treatments.
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